The latest trading day saw Bristol Myers Squibb (BMY) settling at $56.29, representing a -0.16% change from its previous close.
Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...
The FDA has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs with a new active substance in ...
Well, to make those goals a little bit easier to reach, B&M have launched the perfect 2025 fitness hack and there is no need ...
Analysts at Leerink Partnrs boosted their Q4 2024 EPS estimates for Bristol-Myers Squibb in a report released on Sunday, ...
B&M is being praised online after shoppers spot a £15 vase that looks more luxurious than its price tag. Customers have been ...
Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.74 which represents a slight increase of $0.38 or 0.69% from the prior close of $55.36. The stock opened at $55.5 and ...
Valued at a market cap of $113.1 billion, Bristol-Myers Squibb Company (BMY) is a leading global biopharmaceutical company ...
Canada's Barrick Gold has confirmed the suspension of its operations in Mali after the government seized gold stocks from the Loulo-Gounkoto mining complex.
Jefferies analyst Akash Tewari maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) today and set a price target of ...
Wedmont Private Capital grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 29.5% during the 4th ...
Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...